CD 24

Biodesign (ALB9), Cymbus Bioscience (ALB9), Dako (SN389), Immunotech (ALB9), RDI (ALB9) and Serotec (ALB9).

Current antibodies are reactive in fresh-frozen sections and cell preparations only.

Antibodies to CD 24 react with a 42 kD single-chain sialoglycoprotein which is expressed throughout B-cell differentiation but, like other pan-B-cell antigens, is lost following activation and before the secretory (plasma cell) stage. CD 24 is not entirely restricted to B cells and is expressed on granulocytes, interdigitating cells, and renal epithelial cells, as well as some benign and malignant epithelial tumors (Abramson et al, 1981; Kemshed et al, 1982; Melink & LeBien, 1983; Hsu & Jaffe, 1984).

CD 24 is expressed on the majority of precursor B-cell ALL/LBLs and by virtually all mature, TdT-, SIg+ and SIg- B-cell non-Hodgkin's lymphoma (Kersey et al, 1982). It is not found in multiple myeloma nor on benign and neoplastic T cells. Anti-CD 24 has been used for purging bone marrow of B-ALL cells in autologous bone marrow transplantation.

•Abramson CS, Kersey JH, LeBien TW 1981. A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage. Journal of Immunology 126: 83-88.

•Hsu SM, Jaffe ES 1984. Phenotypic expression of B lymphocytes. I. Identification with monoclonal antibodies in normal lymphoid tissues. American Journal of Pathology 144: 387-395.

•Kemshed JT, Fritschy J, Asser U, et al 1982. Monoclonal antibodies defining markers with apparent selectivity for particular hematopoietic cell types may also detect antigens on cells of neural crest origin. Hybridoma 1: 109-123.

•Kersey JH, Abramson C, Perry G et al 1982. Clinical usefulness of monoclonal antibody phenotyping in childhood lymphoblastic leukemia. Lancet 2: 1419-1423.

•Melink GB, LeBien TW 1983. Construction of an antigenic map for human B cell precursors. Journal of Clinical Immunology 3: 260-267.

Manual of diagnostic antibodies for immunohistology / Anthony S.-Y. Leong, Kumarasen Cooper, F. Joel W.-M. Leong.